FDA Updates: Real-Life Proof for Medical Gadgets
Published Date: 12/18/2025
Notice
Summary
The FDA just released updated rules on how real-world data can help approve medical devices faster and smarter. This affects medical device makers and FDA staff by giving clearer, better ways to use everyday health info for decisions. The new guidance starts December 18, 2025, aiming to speed up approvals without extra costs.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Clarifies use of real‑world data
If you are a medical device sponsor or manufacturer, FDA issued final guidance on December 18, 2025 that explains how FDA evaluates real‑world data (RWD) to determine whether they are good enough to generate real‑world evidence (RWE) for regulatory decision‑making. The guidance updates and expands the 2017 RWE guidance and gives recommendations on when RWD sources and study approaches are relevant and reliable.
EUA and CLIA data usability clarified
The guidance provides additional clarity about using clinical data collected from devices authorized under an Emergency Use Authorization (EUA) and describes what types of information could be applicable to support Clinical Laboratory Improvement Amendments (CLIA) determinations, such as a Waiver by Application. This helps sponsors know when EUA‑collected data might be acceptable for certain regulatory or CLIA decisions.
60‑day operational transition period
FDA recognizes that the Agency and industry may need up to 60 days to operationalize the recommendations in this final guidance. For submissions pending after publication on December 18, 2025, and for submissions received within 60 days following that date, FDA generally does not expect sponsors to already include the newly recommended information, though FDA will review any such information if it is submitted.
No new paperwork collections required
The guidance states it contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved FDA collections with listed OMB control numbers. That means the guidance itself does not add new PRA reporting requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-23251 — Submission for OMB Review; 30-Day Comment Request; Special Volunteer and Guest Researcher Assignment (Office of Intramural Research, Office of the Director)
The NIH is asking for a 30-day public comment on their request to keep collecting info from special volunteers and guest researchers. This affects people who work or volunteer in NIH research programs and won’t cost anyone extra money. They want to make sure their forms stay approved and easy to use, so the research keeps running smoothly.
Next: 2025-23255 — Performance Review Board Membership
The USDA just announced the new team members for its Performance Review Boards starting November 18, 2025. These boards help decide how top executives get rated and rewarded, making sure everything’s fair and by the book. If you’re a senior leader at USDA, this update affects how your performance and pay get reviewed.